FindTrial
Sign In

Value of TrueVue three-dimensional imaging combined with automated mitral valve quantification in the local diagnosis and adjunctive intervention of mitral valve prolapse

Value of TrueVue three-dimensional imaging combined with automated mitral valve quantification in the local diagnosis and adjunctive intervention of mitral valve prolapse

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094073
Enrollment
Unknown
Registered
2024-12-17
Start date
2024-12-20
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mitral valve prolapse

Interventions

Case series:None

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Transthoracic echocardiography diagnosis of more than moderate MVP and consideration of TEER treatment; Having complete clinical data;

Exclusion criteria

Exclusion criteria: Excluding those with other cardiac malformations and those with psychiatric and cognitive disorders who are unable to cooperate.

Design outcomes

Primary

MeasureTime frame
Prolapse height;Prolapse width;—

Secondary

MeasureTime frame
Mitral valve orifice area;Length of anterior mitral leaflet;Length of posterior mitral leaflet;Mitral annulus anteroposterior diameter;Mitral annulus left and right diameters;VCW;EROA;Mitral orifice blood flow velocity;—

Countries

China

Contacts

Public ContactFeifei Sun

Shengjing Hospital of China Medical University

1074483265@qq.com+86 182 4265 2252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026